JP Morgan initiates coverage of Iambic Therapeutics with overweight rating; price target $22
IAM•JP Morgan initiated coverage of Iambic Therapeutics with an overweight rating and a $22 price target.
Related News
Aflac Incorporated: Mizuho raises target price to $112 from $107
AFL•
Constellation Energy Q3 adjusted EPS beats estimates on Calpine acquisition impact
CEG•
Datavault AI and Biochar Now combine insured carbon removal credits with patented tokenization technology
DVLT•
CECO Environmental Corp Q3 adjusted EPS USD 0.6
CECO•
British American Tobacco buys back shares worth £27 million
BTI•